Company Overview and News

 
EBOS Group, Ltd. ADR 2018 Q4 - Results - Earnings Call Slides

2018-08-23 seekingalpha
The following slide deck was published by EBOS Group, Ltd. ADR in conjunction with their 2018 Q4 earnings call.
EBOSF EBOSY EBO EBO

 
Ebos profit grows to $272 million

2018-08-22 nzherald.co.nz
Ebos Group boosted annual earnings in line with its forecast even though revenue fell, as the pharmaceutical and animal health products company increased margins and benefited from acquisitions.
EBOSF EBOSY EBO EBO

 
NZ shares lift as Synlait rallies on A2 stake lift

2018-08-03 nzherald.co.nz
New Zealand shares gained, led higher by Synlait Milk as A2 lifted its stake in the company while Freightways and Ebos fell.
KTHDY BGR EBOSF THL PPSHY EBOSY SNZ KMD EBO EBO SML KMD

 
Freightways, Sky TV lead NZ shares gain

2018-07-31 nzherald.co.nz
New Zealand shares gained, led higher by Freightways and Sky Network Television as the market remains quiet ahead of earnings season.
CEN ZNRGF KMD COENF SKT ZNZ GNE SYKWF SKC CEN SKKTY FGHRY KMD GEL KTHDY EBOSY FLT ZEL EBO COENY KWIPF EBOSF EVO GNE GTK EBO

9
Dispensing disruption: Are pharmacies ready for digital rivals?

2018-07-06 theage.com.au
When Amazon announced its purchase last week of online pharmacy PillPack, which packages and delivers pre-sorted doses of prescribed drugs direct to consumers’ homes, major US-based pharmacies from CVS Health to Walgreens saw their share prices fall about 10 per cent.
EBOSF RMYHY API RHC EBOSY CVS EBO RMSYF EBO

9
Dispensing disruption: Are pharmacies ready for digital rivals?

2018-07-06 smh.com.au
When Amazon announced its purchase last week of online pharmacy PillPack, which packages and delivers pre-sorted doses of prescribed drugs direct to consumers’ homes, major US-based pharmacies from CVS Health to Walgreens saw their share prices fall about 10 per cent.
EBOSF RMYHY API RHC EBOSY CVS EBO RMSYF EBO

 
ASX lifts for the week despite the looming trade war

2018-07-06 theage.com.au
The Australian sharemarket has ended the week with a fresh 10-1/2-year high on Friday, despite the US going ahead with tariffs that could potentially begin an all-out trade war with China.
DB API EBOSY EBO RSG EBOSF RMGGY RMGGF MS EBO

 
ASX lifts for the week despite the looming trade war

2018-07-06 smh.com.au
The Australian sharemarket has ended the week with a fresh 10-1/2-year high on Friday, despite the US going ahead with tariffs that could potentially begin an all-out trade war with China.
DB API EBOSY EBO RSG EBOSF RMGGY RMGGF MS EBO

 
NZ shares up; Auckland Airport leads gains

2018-07-05 nzherald.co.nz
New Zealand shares rose in light trading, led higher by Auckland International Airport and Westpac Banking Corp, with Heartland Bank and Fletcher Building softening.
AIA FBU WBC FCREY EBOSY WEBNF WBK ACKDF FRCEF EBO AUKNY EBOSF AIA WBC FBU SKLUY SKL EBO

2
Australian shares advance on strength of major banks

2018-07-03 theage.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF BHP RIO BBL BHP BHPLF EBO

2
Australian shares advance on strength of major banks

2018-07-03 smh.com.au
The Australian sharemarket has recorded only its second advance in the last eight sessions despite a broad retreat of commodity prices overnight.
PILBF RIO DB BLT RIO IAG BEPTF RTPPF GALXF RTNTF MS TWE SML IAUGY PLS TSRYY BHPBF EBOSY EBO BCHEY BPT EBOSF TSRYF GXY IAUGF BHP RIO BBL BHP BHPLF EBO

 
NZX 50 rises 1.2% to new record on Ebos Group gains

2018-07-03 nzherald.co.nz
New Zealand shares jumped to a record with Ebos Group hitting a fresh high while A2 Milk Co and Synlait Milk gained on news they plan to extend their supply contract.
EBOSF NZTCY SPKKY OHE EBOSY SPK NZTCF EBO FTRRF EBO SML

2
Sigma told to 'lick wounds' after Chemist Warehouse hammering

2018-07-02 theage.com.au
Sigma Healthcare's largest investor says the company should take time to lick its wounds rather than rush into new investments, after the loss of its biggest contract cut it projected earnings in half and sent its share price plunging 40 per cent in a single day.
EBOSF EBOSY EBO EBO

2
Sigma told to 'lick wounds' after Chemist Warehouse hammering

2018-07-02 smh.com.au
Sigma Healthcare's largest investor says the company should take time to lick its wounds rather than rush into new investments, after the loss of its biggest contract cut it projected earnings in half and sent its share price plunging 40 per cent in a single day.
EBOSF EBOSY EBO EBO

2
MARKET WRAP: Ebos deal dominates otherwise subdued sharemarket

2018-07-02 nbr.co.nz
Harbour Asset Management analyst Shane Solly says global markets could remain volatile due to US tariffs.
EBOSF EBOSY GTK EBO EBO

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...